Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Exelixis Inc (EXEL)  
$21.88 0.30 (1.35%) as of 4:30 Fri 6/7


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 310,240,000
Market Cap: 6.79(B)
Last Volume: 1,303,478 Avg Vol: 2,431,686
52 Week Range: $18.78 - $24.13
Level I Sector: Industrials
Level II Sector: Diversified Services
Level III Sector: Research Services

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 17.5
Insider 6 Months    : 18.9
Insider 3/6 Months : 36.8
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 425,000 615,000 735,409 735,409
Total Buy Value $8,733,955 $12,666,689 $15,268,727 $15,268,727
Total People Bought 1 1 1 1
Total Buy Transactions 2 3 4 4
Total Shares Sold 88,818 224,987 601,659 1,021,249
Total Sell Value $1,938,121 $5,007,803 $12,908,109 $20,266,173
Total People Sold 5 7 9 12
Total Sell Transactions 6 10 17 28
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 985
  Page 13 of 40  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Senner Christopher J. EVP and CFO   •       –      –    2021-02-03 4 D $22.56 $410,727 D/D (18,206) 296,546     -
   Senner Christopher J. EVP and CFO   •       –      –    2021-02-03 4 A $0.00 $0 D/D 69,156 314,752     -
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2021-02-03 4 D $22.56 $337,994 D/D (14,982) 543,455     -
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2021-02-03 4 A $0.00 $0 D/D 81,038 558,437     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-02-03 4 D $22.56 $451,132 D/D (19,997) 343,790     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-02-03 4 A $0.00 $0 D/D 80,663 363,787     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2021-02-03 4 D $22.56 $346,634 D/D (15,365) 590,798     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2021-02-03 4 A $0.00 $0 D/D 64,409 606,163     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-02-01 4 AS $22.08 $1,435,200 D/D (65,000) 283,124 3%     
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-02-01 4 OE $1.70 $110,500 D/D 65,000 348,124     -
   Senner Christopher J. EVP and CFO   •       –      –    2021-01-12 4 AS $25.00 $750,000 D/D (30,000) 245,596 -3%     
   Senner Christopher J. EVP and CFO   •       –      –    2021-01-12 4 OE $3.66 $109,800 D/D 30,000 275,596     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2021-01-04 4 OE $1.90 $256,100 D/D 50,000 541,754     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-01-04 4 AS $20.32 $1,320,800 D/D (65,000) 283,124 24%     
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-01-04 4 OE $1.70 $110,500 D/D 65,000 348,124     -
   Morrissey Michael M President and CEO   •       •      –    2020-12-28 4 GD $0.00 $0 I/I 126,565 992,309     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2020-12-18 4 AS $20.01 $1,300,650 D/D (65,000) 283,124 23%     
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2020-12-18 4 OE $1.70 $110,500 D/D 65,000 348,124     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2020-12-17 4 GD $0.00 $0 D/D 2,500 491,754     -
   Willsey Lance Director   –       •      –    2020-12-04 4 OE $5.82 $617,746 D/D 106,142 474,415     -
   Marchesi Vincent T Director   –       •      –    2020-11-24 4 S $18.50 $740,074 D/D (40,004) 90,212 -27%     
   Marchesi Vincent T Director   –       •      –    2020-11-24 4 OE $5.82 $232,823 D/D 40,004 130,216     -
   Morrissey Michael M President and CEO   •       •      –    2020-11-20 4 GA $0.00 $0 I/I 187,239 1,118,874     -
   Morrissey Michael M President and CEO   •       •      –    2020-11-20 4 GD $0.00 $0 D/D 187,239 386,641     -
   Haley Patrick J. EVP, Commercial   •       –      –    2020-11-15 4 D $20.16 $210,591 D/D (10,446) 239,245     -
  985 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 13 of 40
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us